In this Section |
201644 Impacts of the Master Settlement Agreement (MSA) on state tobacco control policymaking and health outcomesTuesday, November 10, 2009
The landmark Master Settlement Agreement (MSA), enacted in 1999, involves a transfer of $206 billion from tobacco companies to 46 states spread out over 25 years. (The remaining 4 states receive comparable MSA payments resulting from separate legal proceedings.) These MSA payments are ostensibly to offset the burden of tobacco-related diseases on state Medicaid programs, and to reduce youth smoking rates. However, states are legally free to use their monies for any purpose. Most observers of MSA implementation have suggested that states have decidedly mixed records when it comes to using MSA funds for tobacco control and/or treatment of tobacco-related diseases. There are wide variations in state use of MSA funds for tobacco control/treatment, and there is little state comparative research on the impact of MSA spending on tobacco control outcomes. In this paper, using data from all states, we estimate two econometric models to find the impacts of MSA spending on tobacco control, youth smoking and overall cessation. We use data on MSA payments, MSA spending, state spending on tobacco prevention, the Strength of Tobacco Control Index of state policy activism, and individual health habits over the period of 2000-2008. The analysis relates the use of MSA funds to state tobacco education, regulation, taxation and treatment activities, as well as significant health outcomes. We also estimate the degree to which the MSA has in fact led to improvements in public health, and provide some suggestions as to how the policy effectiveness of MSA spending might be increased.
Learning Objectives: Keywords: Tobacco Policy, Tobacco Control
Presenting author's disclosure statement:
Qualified on the content I am responsible for because: I am an experienced and accomplished public health researcher in health policymaking, particularly tobacco control policymaking. I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.
See more of: Secondhand smoke policies: Best practices and policy implications
See more of: Alcohol, Tobacco, and Other Drugs |